{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:06:38Z","timestamp":1768593998148,"version":"3.49.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0122735","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T02:40:04Z","timestamp":1427596804000},"page":"e0122735","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study"],"prefix":"10.1371","volume":"10","author":[{"given":"Amirrtha","family":"Srikanthan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josee-Lyne","family":"Ethier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ocana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bostjan","family":"Seruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika K.","family":"Krzyzanowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"5600","key":"ref1","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"G Manning","year":"2002","journal-title":"Science"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"DS Krause","year":"2005","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"MH Chen","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1245\/s10434-006-9227-1","article-title":"Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments","volume":"14","author":"N Steeghs","year":"2007","journal-title":"Annals of surgical oncology"},{"issue":"9544","key":"ref5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"GD Demetri","year":"2006","journal-title":"Lancet"},{"issue":"23","key":"ref6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"BJ Druker","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"26","key":"ref7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"CE Geyer","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"23","key":"ref8","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"H Hurwitz","year":"2004","journal-title":"The New England journal of medicine"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"RJ Motzer","year":"2007","journal-title":"The New England journal of medicine"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1172\/JCI31988","article-title":"Applying the discovery of the Philadelphia chromosome","volume":"117","author":"DW Sherbenou","year":"2007","journal-title":"The Journal of clinical investigation"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"DJ Slamon","year":"2001","journal-title":"The New England journal of medicine"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"FA Shepherd","year":"2005","journal-title":"The New England journal of medicine"},{"issue":"4","key":"ref13","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"GK Dy","year":"2013","journal-title":"CA: a cancer journal for clinicians"},{"issue":"32","key":"ref14","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1200\/JCO.2008.18.5439","article-title":"Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?","volume":"26","author":"DJ Lenihan","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: Multi-targeted or single-targeted?","volume":"2","author":"F Broekman","year":"2011","journal-title":"World journal of clinical oncology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","article-title":"Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance","volume":"53","author":"A Levitzki","year":"2013","journal-title":"Annual review of pharmacology and toxicology"},{"issue":"24","key":"ref17","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"S Niraula","year":"2012","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11886-009-0025-9","article-title":"Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue","volume":"11","author":"MH Chen","year":"2009","journal-title":"Current cardiology reports"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ncponc1225","article-title":"Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy","volume":"5","author":"AY Khakoo","year":"2008","journal-title":"Nature clinical practice Oncology"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"TD Kim","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1053\/j.seminoncol.2013.09.010","article-title":"Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management","volume":"40","author":"RM Steingart","year":"2013","journal-title":"Seminars in oncology"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"CN Sternberg","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"22","key":"ref23","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"EL Strevel","year":"2007","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref24","article-title":"Nexavar: Highlights of Prescribing Information Whippany","year":"2013"},{"key":"ref25","unstructured":"Genentech USA Inc. Tarceva: Highlights of Prescribing Information San Francisco, CA: Genentech USA, Inc., A Member of the Roche Group; 2014 [updated July 17, 2014; cited 2014 July 17]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021743s019lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021743s019lbl.pdf<\/ext-link>."},{"key":"ref26","article-title":"Sutent: Highlights of Prescribing Information","year":"2013"},{"key":"ref27","unstructured":"Heart and Stroke Foundation. Statistics: Heart Disease 2014 [updated July 18, 2014; cited 2014 July 18]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.heartandstroke.com\/site\/c.ikIQLcMWJtE\/b.3483991\/k.34A8\/Statistics.htm\" xlink:type=\"simple\">http:\/\/www.heartandstroke.com\/site\/c.ikIQLcMWJtE\/b.3483991\/k.34A8\/Statistics.htm<\/ext-link> - heartdisease."},{"issue":"25","key":"ref28","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects","volume":"25","author":"JR Carver","year":"2007","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"T Eschenhagen","year":"2011","journal-title":"European journal of heart failure"},{"issue":"32","key":"ref30","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"M Schmidinger","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"ML Maitland","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"DJ Lenihan","year":"2013","journal-title":"The oncologist"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"HG Van Spall","year":"2007","journal-title":"JAMA: the journal of the American Medical Association"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2010.33.1462","article-title":"Clinical research: show us the data","volume":"29","author":"A Ocana","year":"2011","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"AJ Templeton","year":"2013","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"ref36","unstructured":"Government of Canada. Population by year, by province and territory 2013 [updated June 15, 2014; cited 2014 2014-06-15]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.statcan.gc.ca\/tables-tableaux\/sum-som\/l01\/cst01\/demo02a-eng.htm\" xlink:type=\"simple\">http:\/\/www.statcan.gc.ca\/tables-tableaux\/sum-som\/l01\/cst01\/demo02a-eng.htm<\/ext-link>."},{"issue":"95","key":"ref37","first-page":"246","article-title":"Cancer registration in Ontario: a computer approach","author":"EA Clarke","year":"1991","journal-title":"IARC scientific publications"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","article-title":"An application of capture-recapture methods to the estimation of completeness of cancer registration","volume":"41","author":"SC Robles","year":"1988","journal-title":"Journal of clinical epidemiology"},{"issue":"2","key":"ref39","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"AR Levy","year":"2003","journal-title":"The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique"},{"key":"ref40","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario Public Drug Programs: Exceptional Access Program (EAP) Reimbursement Criteria 2013 [cited 2014 December 3]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/eap_criteria_list.aspx\" xlink:type=\"simple\">http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/eap_criteria_list.aspx<\/ext-link>."},{"key":"ref41","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario Public Drug Programs: How Drugs Are Approved: Queen&apos;s Printer For Ontario; 2013 [updated May 23; cited 2014 October 7]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/how_drugs_approv\/how_drugs_approv.aspx\" xlink:type=\"simple\">http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/how_drugs_approv\/how_drugs_approv.aspx<\/ext-link>."},{"key":"ref42","unstructured":"Cancer Care Ontario. Cancer Drugs\u2014Frequently Asked Questions Toronto, Ontario2014 [updated January 6; cited 2014 October 7]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.cancercare.on.ca\/cms\/One.aspx?portalId=1377&pageId=11829-1\" xlink:type=\"simple\">https:\/\/www.cancercare.on.ca\/cms\/One.aspx?portalId=1377&amp;pageId=11829-1<\/ext-link>."},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","article-title":"Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm","volume":"25","author":"JE Hux","year":"2002","journal-title":"Diabetes care"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.24095\/hpcdp.33.3.06","article-title":"Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records","volume":"33","author":"SE Schultz","year":"2013","journal-title":"Chronic diseases and injuries in Canada"},{"issue":"1","key":"ref45","first-page":"e18","article-title":"Accuracy of administrative databases in identifying patients with hypertension","volume":"1","author":"K Tu","year":"2007","journal-title":"Open medicine: a peer-reviewed, independent, open-access journal"},{"issue":"7","key":"ref46","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S0828-282X(10)70412-8","article-title":"Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD)","volume":"26","author":"K Tu","year":"2010","journal-title":"The Canadian journal of cardiology"},{"issue":"18","key":"ref47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJM199910283411806","article-title":"Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction","volume":"341","author":"DA Alter","year":"1999","journal-title":"The New England journal of medicine"},{"issue":"15","key":"ref48","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"TM Suter","year":"2013","journal-title":"European heart journal"},{"issue":"5s","key":"ref49","article-title":"Jean; Blatchford, Patrick Jud Blatchford; Ritchie, Christine; Fairclough, Diane; Hanson, Laura; Bull, Janet; PCRC Investigators. Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness","volume":"32","author":"APK Abernethy","year":"2014","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"R Dienstmann","year":"2011","journal-title":"The oncologist"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"S George","year":"2012","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"No 15_suppl","key":"ref52","article-title":"Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC)","volume":"Vol 28","author":"N. Zee YKM","year":"2010","journal-title":"J Clin Oncol, 2010 ASCO Annual Meeting Abstracts"},{"issue":"34","key":"ref53","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"DY Heng","year":"2009","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"H Joensuu","year":"2012","journal-title":"JAMA: the journal of the American Medical Association"},{"issue":"9677","key":"ref55","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"KK Ray","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"ref56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/kisup.2011.5","article-title":"Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease","volume":"1","author":"G London","year":"2011","journal-title":"Kidney international supplements"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1758-5996-6-58","article-title":"Diabetes and cardiovascular disease: from evidence to clinical practice\u2014position statement 2014 of Brazilian Diabetes Society","volume":"6","author":"MC Bertoluci","year":"2014","journal-title":"Diabetology & metabolic syndrome"},{"issue":"Suppl 1","key":"ref58","first-page":"S1","article-title":"Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction","volume":"37","author":"AY Cheng","year":"2013","journal-title":"Canadian journal of diabetes"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamasurg.2013.5076","article-title":"Socioeconomic disparities in mortality after cancer surgery: failure to rescue","volume":"149","author":"BN Reames","year":"2014","journal-title":"JAMA surgery"},{"issue":"5","key":"ref60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1055-9965.EPI-13-0924","article-title":"Impact of neighborhood and individual socioeconomic status on survival after breast cancer varies by race\/ethnicity: the Neighborhood and Breast Cancer Study","volume":"23","author":"S Shariff-Marco","year":"2014","journal-title":"Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"23","key":"ref61","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"L Tao","year":"2014","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0122735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T23:45:56Z","timestamp":1651621556000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0122735"}},"subtitle":[],"editor":[{"given":"Jung Weon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0122735","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}